# Bain Capital Life Sciences Investors, LLC: Form 13F holdings

An institutional investment manager in Boston, MA. SEC CIK 1703031.

- Quarter ended: 2026-06-30
- Filed: 2026-08-14
- Reported value: $1.68bn
- Positions: 21 (21 lines in the filing's table; lines for the same security and option type are added together here)
- Compared with: the 13F for the quarter ended 2026-03-31
- Filing: https://www.sec.gov/Archives/edgar/data/1703031/000119312526350470/

## Holdings

As filed, largest first. Reported value is what the manager stated at the quarter end (Jun 30, 2026), in US dollars; it is filing data, not a price. Weight is the share of the total reported value.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| [KAILERA THERAPEUTICS INC (KLRA)](/companies/klra.md) | COMMON STOCK | $497.5m | 29.6% | 22,583,268 |  | New +22,583,268 |
| [HEARTFLOW INC (HTFL)](/companies/htfl.md) | COM | $247.9m | 14.7% | 8,448,158 |  | Reduced −2,000,000 |
| NEWAMSTERDAM PHARMA COMPANY | ORDINARY SHARES | $129.0m | 7.7% | 3,806,566 |  | Reduced −3,500,000 |
| [SAVARA INC (SVRA)](/companies/svra.md) | COM | $108.4m | 6.4% | 17,600,621 |  | Unchanged |
| ALKERMES PLC | SHS | $101.5m | 6.0% | 1,937,938 |  | Added +1,327,938 |
| [SOLID BIOSCIENCES INC (SLDB)](/companies/sldb.md) | COM NEW | $98.0m | 5.8% | 9,808,819 |  | Unchanged |
| PHARVARIS N V | COM | $92.5m | 5.5% | 2,675,509 |  | Unchanged |
| [OLEMA PHARMACEUTICALS INC (OLMA)](/companies/olma.md) | COM | $88.6m | 5.3% | 7,085,249 |  | Reduced −387,989 |
| [HEMAB THERAPEUTICS HOLDINGS INC (COAG)](/companies/coag.md) | COM SHS | $60.6m | 3.6% | 1,650,000 |  | New +1,650,000 |
| [CABALETTA BIO INC (CABA)](/companies/caba.md) | COM | $53.6m | 3.2% | 17,241,445 |  | Added +7,564,320 |
| [X4 PHARMACEUTICALS INC (XFOR)](/companies/xfor.md) | COM NEW | $37.2m | 2.2% | 7,967,454 |  | Unchanged |
| [DIANTHUS THERAPEUTICS INC (DNTH)](/companies/dnth.md) | COM | $35.3m | 2.1% | 362,470 |  | Unchanged |
| [C4 THERAPEUTICS INC (CCCC)](/companies/cccc.md) | COM STK | $33.5m | 2.0% | 7,171,910 |  | Unchanged |
| [KYVERNA THERAPEUTICS INC (KYTX)](/companies/kytx.md) | COM | $25.7m | 1.5% | 2,885,000 |  | Reduced −225,000 |
| [ANNEXON INC (ANNX)](/companies/annx.md) | COM | $25.3m | 1.5% | 4,437,731 |  | Reduced −774,943 |
| [RAPID MICRO BIOSYSTEMS INC (RPID)](/companies/rpid.md) | CLASS A COM | $14.6m | 0.9% | 8,434,560 |  | Unchanged |
| [DISC MEDICINE INC (IRON)](/companies/iron.md) | COM | $10.3m | 0.6% | 141,234 |  | Unchanged |
| [ATEA PHARMACEUTICALS INC (AVIR)](/companies/avir.md) | COM | $9.7m | 0.6% | 2,075,639 |  | Reduced −284,999 |
| [XILIO THERAPEUTICS INC (XLO)](/companies/xlo.md) | COM | $6.4m | 0.4% | 664,021 |  | Unchanged |
| [UPSTREAM BIO INC (UPB)](/companies/upb.md) | COM | $4.2m | 0.2% | 600,949 |  | Reduced −266,262 |
| NEWAMSTERDAM PHARMA COMPANY | \*W EXP 99/99/999 | $2.1m | 0.1% | 99,999 |  | Unchanged |

## Sold out

Held at the end of the quarter before and not reported this quarter.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| CENTESSA PHARMACEUTICALS | SPONSORED ADS | $0 | 0.0% | 0 |  | Sold out −635,000 |

Source: SEC EDGAR, Form 13F-HR, accession 0001193125-26-350470. Last ingested by Listed: Oct 22, 2026, 05:26 ET. No prices; not investment advice.